Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
暂无分享,去创建一个
R. Winterhalder | G. Bodoky | K. Zaugg | P. Izzo | A. Roth | P. Yan | D. Klingbiel | M. D. Berger | P. Saletti | D. Zwahlen | L. Plasswilm | R. V. Von Moos | D. Koeberle | S. Schacher | S. Hayoz | P. Samaras | D. Rauch | U. Meier | D. Bärtschi | R. von Moos
[1] L. Reggiani Bonetti,et al. Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery? , 2017, World journal of gastroenterology.
[2] J. Park,et al. What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy? , 2015, Cancer research and treatment : official journal of Korean Cancer Association.
[3] D. Shibata,et al. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[4] Eun Ho Kim,et al. The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells. , 2014, Oncology reports.
[5] R. Greil,et al. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. , 2014, Anticancer research.
[6] J. Bergh,et al. LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE) , 2014 .
[7] N. Petrelli,et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] D. Tait,et al. RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. , 2014, European journal of cancer.
[9] Jeffrey W. Clark,et al. Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer , 2014, Journal of Gastrointestinal Cancer.
[10] J. Coffey,et al. KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. , 2013, Surgical oncology.
[11] R. Winterhalder,et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] P. Kienle,et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. , 2012, The Lancet. Oncology.
[13] R. Winterhalder,et al. Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients with locally advanced, K-ras-mutated rectal cancer (LARC): A phase I/II trial (SAKK 41/08). , 2012 .
[14] C. Lathia,et al. Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial , 2011, Journal of clinical pharmacology.
[15] M. Bracko,et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study , 2011, Radiation oncology.
[16] T. Ruhstaller,et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Christophe Hennequin,et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. Ellis,et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. , 2010, International journal of radiation oncology, biology, physics.
[19] T. Beißbarth,et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[20] J. Robertson,et al. Sorafenib and radiation: A promising combination in colorectal and pancreas cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] K. Sheahan,et al. A Simplified Tumor Regression Grade Correlates with Survival in Locally Advanced Rectal Carcinoma Treated with Neoadjuvant Chemoradiotherapy , 2008, Annals of Surgical Oncology.
[22] Bernard Leduc,et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Laurence Collette,et al. Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.
[24] Rainer Fietkau,et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Mazumdar,et al. Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer , 2005, Annals of surgery.
[26] S. Kong,et al. The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells. , 2004, Oncology reports.
[27] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[28] L. Goodglick,et al. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. , 2004, Advances in cancer research.
[29] M. Sigmund,et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] O. Dworak,et al. Pathological features of rectal cancer after preoperative radiochemotherapy , 1997, International Journal of Colorectal Disease.